Develops devices for treating hypertension and artery disease.
Jun 2026Revenue $32.0M/yrExpenses $90.0M/yr
No trendCash runway ≈ 1.9 years from Jun 2026
Figures by year
When will Orchestra BioMed Holdings be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $32.0M and expenses $90.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $33.5M | $85.3M | −$51.8M |
| Dec 2024 | $2.64M | $66.9M | −$64.3M |
| Dec 2023 | $2.76M | $54.3M | −$51.5M |
| Dec 2022 | $3.53M | $36.2M | −$32.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.